Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Dose-finding, Safety and Tolerability Trial of Extended-release Quetiapine in Relapsing-remitting and Progressive Multiple Sclerosis

Next Previous
X
Search
Trial Profile

A Dose-finding, Safety and Tolerability Trial of Extended-release Quetiapine in Relapsing-remitting and Progressive Multiple Sclerosis

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 20 May 2020

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Quetiapine (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions

    • Most Recent Events

    • 20 May 2020 It is given in NCT inclusion NOTE: No longer recruiting RRMS patients, since results are more recent, so retaining as per results.Also, as PMS patients were enrolled (not clear from result which progressive category) and NCT mentioned (primary-progressive, progressive-relapsing, secondary-progressive) so retaining all three for better searchability purpose.Pls update further.
    • 01 May 2020 Results of cohort expansion phase 1 assessing safety and tolerability were presented at the 72nd Annual Meeting of the American Academy of Neurology
    • 06 Oct 2019 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top